Scott and Jenny review the newly released 2026 ADA Standards of Care, praising key updates like hospital safety protocols while critiquing the "slow drift" of official guidance compared to real-world management.

Topics Discussed:

The "Slow Drift" of Guidance: Scott analyzes how standards often lag behind effective real-world management, comparing current advice to guidelines from 2018 and 2022.

GLP-1s for Type 1: The new guidance explicitly lists GLP-1 receptor agonists as a treatment option for obesity in people with Type 1 diabetes.

Technology Access: The requirement for C-Peptide levels or antibody presence has been removed for initiating insulin pumps or AID systems.

Hospital Safety: A crucial new standard mandates that basal insulin should never be held for patients with Type 1 diabetes in the hospital.

Workplace Advocacy: New language supports reasonable accommodations for adults using diabetes technology (pumps/CGMs) in the workplace.

Cannabis Warning: The standards include a new specific warning against cannabis use for those at risk of DKA due to concerns about "cannabis hyperemesis syndrome".

#1728 ADA Standards of Care for 2026